MD20150006A2 - Inhibitori de micro-ARN din familia miR-15 - Google Patents
Inhibitori de micro-ARN din familia miR-15 Download PDFInfo
- Publication number
- MD20150006A2 MD20150006A2 MDA20150006A MD20150006A MD20150006A2 MD 20150006 A2 MD20150006 A2 MD 20150006A2 MD A20150006 A MDA20150006 A MD A20150006A MD 20150006 A MD20150006 A MD 20150006A MD 20150006 A2 MD20150006 A2 MD 20150006A2
- Authority
- MD
- Moldova
- Prior art keywords
- mir
- family
- oligonucleotides
- rnas
- inhibitors
- Prior art date
Links
- 108091057645 miR-15 stem-loop Proteins 0.000 title abstract 3
- 108091070501 miRNA Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- -1 miR-15a Proteins 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 108091031326 miR-15b stem-loop Proteins 0.000 abstract 2
- 108091027943 miR-16 stem-loop Proteins 0.000 abstract 2
- 108091030938 miR-424 stem-loop Proteins 0.000 abstract 2
- 108091063340 miR-497 stem-loop Proteins 0.000 abstract 2
- 239000002679 microRNA Substances 0.000 abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662772P | 2012-06-21 | 2012-06-21 | |
| US201361780352P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/046960 WO2013192486A1 (en) | 2012-06-21 | 2013-06-21 | Inhibitors of the mir-15 family of micro-rnas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD20150006A2 true MD20150006A2 (ro) | 2015-06-30 |
Family
ID=49769409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20150006A MD20150006A2 (ro) | 2012-06-21 | 2013-06-21 | Inhibitori de micro-ARN din familia miR-15 |
Country Status (17)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107236735B (zh) | 2012-06-21 | 2019-11-08 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| WO2014145356A1 (en) | 2013-03-15 | 2014-09-18 | MiRagen Therapeutics, Inc. | Bridged bicyclic nucleosides |
| US10443044B2 (en) | 2014-04-17 | 2019-10-15 | Ips Heart | Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds |
| KR20170042625A (ko) | 2014-08-04 | 2017-04-19 | 미라젠 세러퓨틱스 인코포레이티드 | Myh7b의 억제제 및 이의 용도 |
| US9487783B2 (en) | 2014-08-07 | 2016-11-08 | Regulus Therapeutics Inc. | Targeting microRNAs for metabolic disorders |
| BR112017015618A2 (pt) | 2015-01-20 | 2018-04-10 | Miragen Therapeutics Inc | inibidores de mir-92 e usos destes. |
| WO2017219170A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用 |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| CN106692175A (zh) * | 2016-12-26 | 2017-05-24 | 大连医科大学附属第二医院 | miR‑665‑3p抑制物在制备防治缺血再灌注损伤药物中的应用 |
| US10941403B2 (en) | 2018-04-02 | 2021-03-09 | Oregon Health & Science University | Microrna inhibitors as anti-cancer therapeutics |
| EP4005602A4 (en) | 2019-07-30 | 2024-06-12 | Shionogi & Co., Ltd | NUCLEIC ACID AGENT TARGETED AGAINST MURF1 |
| CN116438305A (zh) * | 2020-07-23 | 2023-07-14 | 法兰克福大学 | 用于治疗心力衰竭的miRNA的组合抑制 |
| CN113599540B (zh) * | 2021-05-27 | 2023-05-23 | 山西医科大学 | miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2462144C (en) | 2001-09-28 | 2016-09-20 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Micro-rna molecules |
| CA2524569C (en) | 2002-05-03 | 2013-10-22 | Duke University | A method of regulating gene expression |
| US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
| CA2504605C (en) | 2002-11-13 | 2016-01-19 | Thomas Jefferson University | Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15 |
| EP2474631B1 (en) | 2002-12-20 | 2014-02-12 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| WO2004076622A2 (en) | 2003-02-10 | 2004-09-10 | National Institute Of Advanced Industrial Science And Technology | Regulation of gene expression by dna interference |
| US8145436B2 (en) | 2003-07-15 | 2012-03-27 | The Trustees Of The University Of Pennsylvania | Method and systems for identifying micro-RNA targets and synthesizing novel micro-RNAs and uses of the same |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
| JPWO2005028648A1 (ja) | 2003-09-22 | 2007-11-15 | 愛知県 | リンパ腫の病型および予後診断方法 |
| WO2005040419A1 (en) | 2003-10-14 | 2005-05-06 | Novartis Ag | Oligonucleotide microarray |
| CA2545944A1 (en) | 2003-11-13 | 2005-06-02 | Board Of Regents, The University Of Texas System | Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| US7674617B2 (en) | 2003-12-15 | 2010-03-09 | College of Medicine, Pochon Cha University Industry -Academic Cooperation Foundation | MiRNA molecules isolated from human embryonic stem cell |
| US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| EP1713938A2 (en) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| WO2005079397A2 (en) | 2004-02-13 | 2005-09-01 | Rockefeller University | Anti-microrna oligonucleotide molecules |
| US8088902B2 (en) | 2004-04-05 | 2012-01-03 | The Rockefeller University | DNA virus microRNA and methods for inhibiting same |
| US20060134639A1 (en) | 2004-04-06 | 2006-06-22 | Huffel Christophe V | Method for the determination of cellular transcriptional regulation |
| US20050260648A1 (en) | 2004-04-06 | 2005-11-24 | Huffel Christophe V | Method for the determination of cellular transcriptional |
| CN1961081B (zh) | 2004-04-07 | 2012-09-05 | 埃克斯魁恩公司 | 用于定量微rna和小干扰rna的新方法 |
| EP1771563A2 (en) | 2004-05-28 | 2007-04-11 | Ambion, Inc. | METHODS AND COMPOSITIONS INVOLVING MicroRNA |
| US7582744B2 (en) | 2004-08-10 | 2009-09-01 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| EP1797183B1 (en) | 2004-09-02 | 2012-08-01 | Yale University | Regulation of oncogenes by micrornas |
| FR2877350B1 (fr) | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
| WO2008073922A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro rnas |
| EP1838852A2 (en) | 2004-11-12 | 2007-10-03 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| US9550990B2 (en) | 2004-12-10 | 2017-01-24 | Ionis Pharmaceuticals, Inc. | Regulation of epigenetic control of gene expression |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| US20060166920A1 (en) | 2005-12-27 | 2006-07-27 | Regents Of The University Of Michigan | Oligonucleotide based therapeutics |
| WO2006069584A2 (en) * | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
| JP2006292367A (ja) | 2005-04-05 | 2006-10-26 | Mitsubishi Rayon Co Ltd | ｍｉＲＮＡ検出用マイクロアレイ |
| CA2604333A1 (en) | 2005-04-15 | 2006-10-19 | Cenix Bioscience Gmbh | Human marker genes and agents for cardiovascular disorders and artherosclerosis |
| CA2604807C (en) | 2005-04-19 | 2018-06-12 | Basf Plant Science Gmbh | Improved methods controlling gene expression |
| CN101287834B (zh) | 2005-05-27 | 2016-11-09 | 圣拉法埃莱医院有限公司 | 基因载体 |
| WO2007053184A2 (en) | 2005-05-31 | 2007-05-10 | Cold Spring Harbor Laboratory | Methods for producing micrornas |
| US20070054287A1 (en) | 2005-05-31 | 2007-03-08 | Applera Corporation | Method for identifying medically important cell populations using micro rna as tissue specific biomarkers |
| US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US20070123482A1 (en) | 2005-08-10 | 2007-05-31 | Markus Stoffel | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| CN101426912A (zh) | 2005-08-17 | 2009-05-06 | 瑟纳治疗公司 | 介导rna干扰的化学修饰短干扰核酸分子 |
| EP2796554A3 (en) | 2005-09-12 | 2014-12-10 | The Ohio State University Research Foundation | Compositions for use in treating BCL2-associated cancers |
| US20070092882A1 (en) | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| CA2630952A1 (en) | 2005-11-21 | 2007-05-24 | Johnson & Johnson Research Pty Limited | Multitargeting interfering rnas having two active strands and methods for their design and use |
| US20070259827A1 (en) | 2006-01-25 | 2007-11-08 | University Of Massachusetts | Compositions and methods for enhancing discriminatory RNA interference |
| WO2007092181A2 (en) | 2006-01-26 | 2007-08-16 | Unversity Of Massachusetts | Compositions and methods for modulating translational repression |
| AU2007212700A1 (en) | 2006-01-26 | 2007-08-16 | University Of Massachusetts | RNA interference agents for therapeutic use |
| JP5213723B2 (ja) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ， インコーポレーテッド | マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物 |
| WO2007095387A2 (en) | 2006-02-17 | 2007-08-23 | Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| WO2007103808A2 (en) | 2006-03-02 | 2007-09-13 | The Ohio State University | Microrna expression profile associated with pancreatic cancer |
| EP2007889A2 (en) | 2006-04-03 | 2008-12-31 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
| US20080220423A1 (en) | 2006-05-19 | 2008-09-11 | Soren Moller | Oligonucleotide probes useful for detection and analysis of microRNA precursors |
| WO2007147067A2 (en) | 2006-06-14 | 2007-12-21 | Rosetta Inpharmatics Llc | Methods and compositions for regulating cell cycle progression |
| EP2035446A2 (en) | 2006-06-19 | 2009-03-18 | Københavns Universitet (University of Copenhagen) | Ribozyme mediated stabilization of polynucleotides |
| WO2008024499A2 (en) | 2006-08-25 | 2008-02-28 | Duke University | Methods for in vivo identification of endogenous mrna targets of micrornas |
| AU2007299748A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | miR-15, miR-26, miR -31,miR -145, miR-147, miR-188, miR-215, miR-216 miR-331, mmu-miR-292-3p regulated genes and pathways as targets for therapeutic intervention |
| US20090306181A1 (en) | 2006-09-29 | 2009-12-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| JP2010505427A (ja) | 2006-10-09 | 2010-02-25 | ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ | 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ） |
| WO2008147430A2 (en) | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| EP2097527B1 (en) | 2006-11-23 | 2018-08-01 | Querdenker Aps | Oligonucleotides for modulating target rna activity |
| AU2007333108A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-126 regulated genes and pathways as targets for therapeutic intervention |
| AU2007333107A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
| CA2671302A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mirna regulated genes and pathways as targets for therapeutic intervention |
| EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
| US20090137504A1 (en) | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
| CA2671270A1 (en) | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
| US20080287383A1 (en) | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
| WO2008112226A2 (en) | 2007-03-13 | 2008-09-18 | Massachusetts Institute Of Technology | Cre-lox based gene knockdown constructs and methods of use thereof |
| AU2008232316A1 (en) | 2007-03-26 | 2008-10-02 | Newcastle Innovation Limited | Therapeutic targets and molecules |
| WO2008147839A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
| WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| AU2008275877B2 (en) | 2007-07-18 | 2015-01-22 | The Regents Of The University Of Colorado, A Body Corporate | Differential expression of microRNAs in nonfailing versus failing human hearts |
| US20090092980A1 (en) | 2007-07-20 | 2009-04-09 | Christoph Arenz | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES |
| WO2009044895A1 (ja) | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | 標的遺伝子の発現を抑制する組成物 |
| MX2010003299A (es) | 2007-10-04 | 2010-04-14 | Santaris Pharma As | Oligonucleotidos muy cortos (micromirs). |
| US8389485B2 (en) | 2007-10-29 | 2013-03-05 | University Of Massachusetts | Encapsulated nanoparticles for nucleic acid delivery |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| NZ585209A (en) | 2007-11-09 | 2012-08-31 | Univ Texas | Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair |
| WO2009066967A2 (en) * | 2007-11-23 | 2009-05-28 | Panagene Inc. | Microrna antisense pnas, compositions comprising the same, and methods for using and evaluating the same |
| CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
| EP2279267A4 (en) | 2008-03-27 | 2012-01-18 | Vascular Biosciences Inc | METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES |
| US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| US20100113284A1 (en) | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
| EP2285960B1 (en) | 2008-05-08 | 2015-07-08 | Asuragen, INC. | Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis |
| WO2009149182A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| WO2010036939A2 (en) | 2008-09-26 | 2010-04-01 | University Of Southern California | A system for synergistic expression of multiple small functional rna elements |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| WO2010126355A1 (en) | 2009-04-29 | 2010-11-04 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure |
| AU2010258875A1 (en) | 2009-06-08 | 2012-01-19 | Miragen Therapeutics | Chemical modification motifs for miRNA inhibitors and mimetics |
-
2013
- 2013-06-19 US US13/921,537 patent/US9163235B2/en not_active Expired - Fee Related
- 2013-06-21 TW TW102122289A patent/TW201406774A/zh unknown
- 2013-06-21 EP EP13806131.2A patent/EP2863956A4/en not_active Withdrawn
- 2013-06-21 EA EA201590070A patent/EA201590070A1/ru unknown
- 2013-06-21 IN IN10899DEN2014 patent/IN2014DN10899A/en unknown
- 2013-06-21 MD MDA20150006A patent/MD20150006A2/ro not_active Application Discontinuation
- 2013-06-21 MX MX2014015641A patent/MX2014015641A/es unknown
- 2013-06-21 CN CN201380039961.7A patent/CN104540527A/zh active Pending
- 2013-06-21 BR BR112014032239A patent/BR112014032239A2/pt not_active IP Right Cessation
- 2013-06-21 WO PCT/US2013/046960 patent/WO2013192486A1/en not_active Ceased
- 2013-06-21 CA CA2876105A patent/CA2876105A1/en not_active Abandoned
- 2013-06-21 AU AU2013277033A patent/AU2013277033A1/en not_active Abandoned
- 2013-06-21 HK HK15110356.0A patent/HK1209621A1/xx unknown
- 2013-06-21 KR KR1020157001535A patent/KR20150036140A/ko not_active Withdrawn
- 2013-06-21 JP JP2015518597A patent/JP2015525081A/ja active Pending
- 2013-06-21 SG SG11201408460UA patent/SG11201408460UA/en unknown
- 2013-06-24 AR ARP130102219 patent/AR091539A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201590070A1 (ru) | 2015-04-30 |
| KR20150036140A (ko) | 2015-04-07 |
| HK1209621A1 (en) | 2016-04-08 |
| WO2013192486A1 (en) | 2013-12-27 |
| EP2863956A4 (en) | 2016-01-20 |
| US9163235B2 (en) | 2015-10-20 |
| JP2015525081A (ja) | 2015-09-03 |
| IN2014DN10899A (cg-RX-API-DMAC7.html) | 2015-09-11 |
| CA2876105A1 (en) | 2013-12-27 |
| BR112014032239A2 (pt) | 2017-08-01 |
| AR091539A1 (es) | 2015-02-11 |
| AU2013277033A1 (en) | 2015-01-22 |
| US20130345288A1 (en) | 2013-12-26 |
| TW201406774A (zh) | 2014-02-16 |
| SG11201408460UA (en) | 2015-01-29 |
| EP2863956A1 (en) | 2015-04-29 |
| CN104540527A (zh) | 2015-04-22 |
| MX2014015641A (es) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20150006A2 (ro) | Inhibitori de micro-ARN din familia miR-15 | |
| MX2013005875A (es) | Inhibidores de microarn que comprenden nucleotidos bloqueados. | |
| ZA202002019B (en) | Serpinc1 irna compositions and methods of use thereof | |
| MX355408B (es) | Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. | |
| MX2021015290A (es) | Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3). | |
| MX2018013216A (es) | Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6). | |
| MX385048B (es) | Composiciones y metodos para inhibir la expresion del gen alas1. | |
| HK1211317A1 (en) | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| MX359548B (es) | Agentes de iarn modificados. | |
| MX2020004986A (es) | Composiciones mejoradas para tratar distrofia muscular. | |
| UA115652C2 (uk) | Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21 | |
| WO2012142313A8 (en) | Micro-rna inhibitors and their uses in disease | |
| PH12016500574A1 (en) | Compositions and methods for inhibiting expression of the alas1 gene | |
| MX2018006445A (es) | Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos. | |
| MX368084B (es) | siRNA Y SU USO EN LA PREPARACIÓN DE UN MEDICAMENTO PARA USARSE EN UN MÉTODO PARA EL TRATAMIENTO DE UN TRANSTORNO OCULAR. | |
| PL398796A1 (pl) | Zastosowanie czasteczek miRNA oraz antagomiru dla miRNA w diagnostyce, zapobieganiu i leczeniu stwardnienia rozsianego | |
| NZ728207A (en) | Oligonucleotide-based inhibitors comprising locked nucleic acid motif | |
| NZ776080A (en) | Modified rnai agents | |
| MA37789A1 (fr) | Inhibiteurs de la famille mir-15 de micro-arn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Abandonment or withdrawal of application (patent for invention) |